The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1761
ISSUE1761
August 17, 2026
Adult Immunization
| Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Adult Immunization
August 17, 2026 (Issue: 1761)
The CDC Advisory Committee on Immunization Practices
(ACIP) recommends certain vaccines for adults residing in
the US. The American Academy of Family Physicians has
also recently published an adult immunization schedule.
Recommendations for...more
- AP Wodi et al. Advisory Committee on Immunization Practices recommended immunization schedule for adults aged 19 years or older – United States, 2025. MMWR Morb Mortal Wkly Rep 2025; 74:30. doi:10.15585/mmwr.mm7402a3
- CDC. Adult immunization schedule by age (addendum updated July 2, 2025). Available at: https://bit.ly/4fD5mgB. Accessed July 30, 2026.
- AAFP. Immunizations and vaccines for family physicians. Available at: https://bit.ly/4yJNuJF. Accessed July 30, 2026.
- FP Havers et al. Use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccines: updated recommendations of the Advisory Committee on Immunization Practices – United States, 2019. MMWR Morb Mortal Wkly Rep 2020; 69:77. doi:10.15585/mmwr.mm6903a5
- CDC. Measles cases and outbreaks. July 24, 2026. Available at: https://bit.ly/4fD8Rnf. Accessed July 30, 2026.
- CDC. Chapter 9: Mumps. In: Manual for the Surveillance of Vaccine-Preventable Diseases. June 18, 2025. Available at: https://bit.ly/4vPRgOR. Accessed July 30, 2026.
- HQ McLean et al. Prevention of measles, rubella, congenital rubella syndrome, and mumps, 2013: summary recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2013; 62(RR-4):1.
- E Krow-Lucal et al. Measles, mumps, rubella vaccine (PRIORIX): recommendations of the Advisory Committee on Immunization Practices – United States, 2022. MMWR Morb Mortal Wkly Rep 2022; 71:1465. doi:10.15585/mmwr.mm7146a1
- M Marin et al. Recommendation of the Advisory Committee on Immunization Practices for use of a third dose of mumps virus-containing vaccine in persons at increased risk for mumps during an outbreak. MMWR Morb Mortal Wkly Rep 2018; 67:33. doi:10.15585/mmwr.mm6701a7
- M Marin et al. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2007; 56(RR-4):1.
- Shingrix – an adjuvanted, recombinant herpes zoster vaccine. Med Lett Drugs Ther 2017; 59:195.
- O Zerbo et al. Effectiveness of recombinant zoster vaccine against herpes zoster in a real-world setting. Ann Intern Med 2024; 177:189. doi:10.7326/m23-2023
- HF Tseng et al. Effectiveness of the adjuvanted recombinant zoster vaccine in adults >50 years in the United States. Clin Infect Dis 2026; 81:e717. doi:10.1093/cid/ciaf329
- S Dos Reis et al. Reduced risk of dementia with recombinant zoster vaccine in US adults age 65 or older. Alzheimers Dement 2026; 22:e71407. doi:10.1002/alz.71407
- In brief: Shingrix for immunocompromised adults. Med Lett Drugs Ther 2021; 63:129.
- KL Dooling et al. Recommendations of the Advisory Committee on Immunization Practices for use of herpes zoster vaccines. MMWR Morb Mortal Wkly Rep 2018; 67:103. doi:10.15585/mmwr.mm6703a5
- TC Anderson et al. Use of recombinant zoster vaccine in immunocompromised adults aged ≥19 years: recommendations of the Advisory Committee on Immunization Practices – United States, 2022. MMWR Morb Mortal Wkly Rep 2022; 71:80. doi:10.15585/mmwr.mm7103a2
- FDA Safety Communication. FDA requires a warning about Guillain-Barré Syndrome (GBS) be included in the prescribing information for Shingrix. March 24, 2021. Available at: https://bit.ly/3lmyvC6. Accessed July 30, 2026.
- Two vaccines (Arexvy and Abrysvo) for prevention of RSV disease. Med Lett Drugs Ther 2023; 65:153.
- In brief: RSV vaccine (Arexvy) for ages 50-59. Med Lett Drugs Ther 2024; 66:113.
- In brief: RSV vaccine (Arexvy) for ages 18-49. Med Lett Drugs Ther 2026; 68:77.
- A new RSV vaccine (mResvia) for adults ≥60 years old. Med Lett Drugs Ther 2024; 66:166.
- A Britton et al. Use of respiratory syncytial virus vaccines in adults aged ≥60 years: updated recommendations of the Advisory Committee on Immunization Practices – United States, 2024. MMWR Morb Mortal Wkly Rep 2024; 73:696. doi:10.15585/mmwr.mm7332e1
- CDC. RSV vaccine guidance for adults. February 24, 2026. Available at: https://bit.ly/3RfWLs8. Accessed July 30, 2026.
- CS Tan et al. IDSA 2025 guidelines on the use of vaccines for the prevention of seasonal RSV infections in immunocompromised patients. Clin Infect Dis 2026 Mar 2 (epub). doi:10.1093/cid/ciag117
- AMA. Vaccine recommendations. March 2, 2026. Available at: https://bit.ly/4hlv1gn. Accessed July 30, 2026.
- In brief: New warning for the RSV vaccines Arexvy and Abrysvo. Med Lett Drugs Ther 2025; 67:31.
- M Kobayashi et al. Expanded recommendations for use of pneumococcal conjugate vaccines among adults aged ≥50 years: recommendations of the Advisory Committee on Immunization Practices – United States, 2024. MMWR Morb Mortal Wkly Rep 2025; 74:1. doi:10.15585/mmwr.mm7401a1
- Capvaxive – a 21-valent pneumococcal conjugate vaccine. Med Lett Drugs Ther 2024; 66:161.
- E Meites et al. Human papillomavirus vaccination for adults: updated recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep 2019; 68:698. doi:10.15585/mmwr.mm6832a3
- Gardasil 9 – a broader HPV vaccine. Med Lett Drugs Ther 2015; 57:47.
- T Kitano and S Yoshida. Nine-valent human papillomavirus vaccination and related cancers in males. JAMA Oncol 2026; 12:592. doi:10.1001/jamaoncol.2026.0496
- I Maldonado et al. Effectiveness, immunogenicity, and safety of the quadrivalent HPV vaccine in women and men aged 27-45 years. Hum Vaccin Immunother 2022; 18:2078626. doi:10.1080/21645515.2022.2078626
- J Restrepo et al. Ten-year follow-up of 9-valent human papillomavirus vaccine: immunogenicity, effectiveness, and safety. Pediatrics 2023; 152:e2022060993. doi:10.1542/peds.2022-060993
- AR Kreimer et al. Noninferiority of one HPV vaccine dose to two doses. N Engl J Med 2025; 393:2421. doi:10.1056/nejmoa2506765
- CDC. Hepatitis B surveillance. April 15, 2025. Available at: http://bit.ly/4vWFqCM. Accessed July 30, 2026.
- MK Weng et al. Universal hepatitis B vaccination in adults aged 19-59 years: updated recommendations of the Advisory Committee on Immunization Practices – United States, 2022. MMWR Morb Mortal Wkly Rep 2022; 71:477. doi:10.15585/mmwr.mm7113a1
- A two-dose hepatitis B vaccine for adults (Heplisav-B). Med Lett Drugs Ther 2018; 60:17.
- S Schillie et al. Prevention of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices. MMWR Recomm Rep 2018; 67(RR-1):1. doi:10.15585/mmwr.rr6701a1
- S Schillie et al. Recommendations of the Advisory Committee on Immunization Practices for use of a hepatitis B vaccine with a novel adjuvant. MMWR Morb Mortal Wkly Rep 2018; 67:455. doi:10.15585/mmwr.mm6715a5
- HM Soeters et al. University-based outbreaks of meningococcal disease caused by serogroup B, United States, 2013-2018. Emerg Infect Dis 2019; 25:434. doi:10.3201/eid2503.181574
- TJ Doyle et al. Concurrent outbreaks of hepatitis A, invasive meningococcal disease, and mpox, Florida, USA, 2021-2022. Emerg Infect Dis 2024; 30:633. doi:10.3201/eid3004.231392
- CDC. Meningococcal disease surveillance and trends. June 4, 2026. Available at: https://bit.ly/4wueL19. Accessed July 30, 2026.
- MenQuadfi – a new meningococcal (A, C, W, and Y) vaccine. Med Lett Drugs Ther 2021; 63:78.
- Penbraya: a pentavalent meningococcal vaccine. Med Lett Drugs Ther 2024; 66:43.
- Penmenvy: a second pentavalent meningococcal vaccine. Med Lett Drugs Ther 2025; 67:57.
- SA Mbaeyi et al. Meningococcal vaccination: recommendations of the Advisory Committee on Immunization Practices, United States, 2020. MMWR Recomm Rep 2020; 69(RR-9):1. doi:10.15585/mmwr.rr6909a1
- In brief: New meningococcal serogroup B vaccination recommendations. Med Lett Drugs Ther 2020; 62:191.
- AB Amin et al. Use of the GSK MenACWY-CRM/MenB-4C pentavalent meningococcal vaccine among persons aged ≥10 years: recommendations of the Advisory Committee on Immunization Practices – United States, 2025. MMWR Morb Mortal Wkly Rep 2026; 75:7. doi:10.15585/mmwr.mm7501a2
- M Doshani et al. Recommendations of the Advisory Committee on Immunization Practices for use of hepatitis A vaccine for persons experiencing homelessness. MMWR Morb Mortal Wkly Rep 2019; 68:153. doi:10.15585/mmwr.mm6806a6
- NP Nelson et al. Prevention of hepatitis A virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices, 2020. MMWR Recomm Rep 2020; 69(RR-5):1. doi:10.15585/mmwr.rr6905a1
- HM Soeters et al. Current epidemiology and trends in invasive Haemophilus influenzae disease–United States, 2009-2015. Clin Infect Dis 2018; 67:881. doi:10.1093/cid/ciy187
- EC Briere et al. Prevention and control of Haemophilus influenzae type b disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2014; 63(RR-1):1.
- S Kidd et al. Use of inactivated polio vaccine among U.S. adults: updated recommendations of the Advisory Committee on Immunization Practices – United States, 2023. MMWR Morb Mortal Wkly Rep 2023; 72:1327. doi:10.15585/mmwr.mm7249a3
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this article? Gain access below.
Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App
- FREE online per issue CME/CE
Purchase this article:
Title: Adult Immunization
Article code: 1761a
Article code: 1761a
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.